In last trading session, Fulcrum Therapeutics Inc (NASDAQ:FULC) saw 0.73 million shares changing hands with its beta currently measuring 2.11. Company’s recent per share price level of $3.12 trading at $0.22 or 7.59% at ring of the bell on the day assigns it a market valuation of $168.42M. That closing price of FULC’s stock is at a discount of -279.81% from its 52-week high price of $11.85 and is indicating a premium of 10.9% from its 52-week low price of $2.78. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.48 million shares which gives us an average trading volume of 656.43K if we extend that period to 3-months.
For Fulcrum Therapeutics Inc (FULC), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.57. Splitting up the data highlights that, out of 13 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 4 suggested the stock as a Hold whereas 9 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.32 in the current quarter.
Fulcrum Therapeutics Inc (NASDAQ:FULC) trade information
Upright in the green during last session for gaining 7.59%, in the last five days FULC remained trading in the red while hitting it’s week-highest on Friday, 03/14/25 when the stock touched $3.12 price level, adding 2.8% to its value on the day. Fulcrum Therapeutics Inc’s shares saw a change of -33.62% in year-to-date performance and have moved -0.64% in past 5-day. Fulcrum Therapeutics Inc (NASDAQ:FULC) showed a performance of -12.36% in past 30-days. Number of shares sold short was 4.92 million shares which calculate 12.91 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 4 to the stock, which implies a rise of 22.0% to its current value. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 23. It follows that stock’s current price would jump 35.9% in reaching the projected high whereas dropping to the targeted low would mean a gain of 35.9% for stock’s current value.
Fulcrum Therapeutics Inc (FULC) estimates and forecasts
This year revenue growth is estimated to fall -100.00% from the last financial year’s standing.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 54.59% during past 5 years.
Fulcrum Therapeutics Inc (NASDAQ:FULC)’s Major holders
Insiders are in possession of 1.87% of company’s total shares while institution are holding 97.18 percent of that, with stock having share float percentage of 99.03%. Investors also watch the number of corporate investors in a company very closely, which is 97.18% institutions for Fulcrum Therapeutics Inc that are currently holding shares of the company. RA CAPITAL MANAGEMENT, L.P. is the top institutional holder at FULC for having 11.61 million shares of worth $71.98 million. And as of 2024-06-30, it was holding 18.6636 of the company’s outstanding shares.
The second largest institutional holder is RTW INVESTMENTS, LP, which was holding about 5.85 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.3979 of outstanding shares, having a total worth of $36.24 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.85 shares of worth $5.78 million or 3.43% of the total outstanding shares. The later fund manager was in possession of 1.71 shares on Dec 31, 2024 , making its stake of worth around $5.32 million in the company or a holder of 3.16% of company’s stock.
